青少年转换多替拉韦与体重指数变化率增加相关
该回顾性观察队列纳入460名病毒学抑制的10-19岁HIV青少年,分析转换多替拉韦前后各1年的BMI变化。转换后BMI年增长速率从0.3 kg/m2升至1.2 kg/m2,女性增幅大于男性。提示转换多替拉韦与BMI变化率增加相关。
要点
- 病毒学抑制青少年转换多替拉韦后BMI年增长速率由0.3升至1.2 kg/m2。
- 女性转换后BMI变化率增加1.1 kg/m2/年,男性增加0.6 kg/m2/年。
- 需进一步研究机制及更长疗程下多替拉韦对青少年BMI的影响。
核心结论
- 病毒学抑制的10-19岁青少年转换多替拉韦与BMI变化率增加相关。
- 女性青少年转换后BMI变化率增幅可能大于男性。
研究设计与样本
- 回顾性观察队列,纳入460名病毒学抑制(<200 copies/mL)的HIV青少年,地点为埃斯瓦蒂尼临床中心。
- 分析转换多替拉韦前1年至转换后1年的BMI测量,采用随机效应线性样条模型描述转换前后BMI变化速率。
主要发现
- 转换多替拉韦前BMI年增长速率为0.3 kg/m2/年,转换后为1.2 kg/m2/年。
- 女性转换后BMI变化率增加1.1 kg/m2/年,男性增加0.6 kg/m2/年。
临床怎么用
- 对病毒学抑制的青少年启动或转换多替拉韦时,应关注体重和BMI变化,尤其女性。
局限性
- 为回顾性观察性队列,尚未阐明多替拉韦影响BMI的机制。
- 需进一步评估更长治疗时间下多替拉韦对青少年BMI的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antiretroviral therapy (ART) regimens that contain dolutegravir (DTG) have been associated with increases in body mass index (BMI) in adults. However, this relationship has not been well described in adolescents. METHODS: In a retrospective observational cohort of 460 virally suppressed (<200 copies/mL) adolescents living with human immunodeficiency virus at a clinical site in Eswatini, body mass index (BMI) measurements were analyzed between 1 year prior to the transition to DTG and up to 1 year after DTG transition. Random-effects linear spline models were used to describe the rate of change in BMI before and after the transition to DTG. RESULTS: In adolescents, BMI increased at a rate of 0.3 kg/m2 per year before DTG transition and increased to a rate of 1.2 kg/m2 per year after DTG transition. Sex of the adolescent modified the relationship between DTG and rate of BMI change: BMI rate of change after DTG transition was increased by 1.1 kg/m2 in females and 0.6 kg/m2 per year in males. CONCLUSIONS: Transition to DTG in virally suppressed adolescents (aged 10-19 years) is associated with an increase in the rate of BMI change. Female adolescents may experience a larger change than males. Further investigation is required to elucidate the mechanism that underlies these observations and to assess how DTG impacts BMI in adolescents following longer durations of treatment.
引用
- Thivalapill N, Simelane T, Mthethwa N, et al. Transition to Dolutegravir Is Associated With an Increase in the Rate of Body Mass Index Change in a Cohort of Virally Suppressed Adolescents. Clin Infect Dis. 2021. PMID: 33119739. doi:10.1093/cid/ciaa1652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。